Last reviewed · How we verify
SUGAMMADEX SODIUM
At a glance
| Generic name | SUGAMMADEX SODIUM |
|---|---|
| Modality | Oligosaccharide |
| Phase | FDA-approved |
| First approval | 2008 |
Approved indications
Common side effects
- Vomiting
- Pain
- Nausea
- Hypotension
- Headache
Serious adverse events
- Anaphylaxis
- Anaphylactic shock
- Hypersensitivity reactions
- Bronchospasm
- Pulmonary obstructive events
- Severe hypotension
- Recurrence of neuromuscular blockade
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old (PHASE4)
- Sugammadex and Menstrual Cycle in Postoperative Nausea and Vomiting
- The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery (PHASE4)
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Comparison of the Performances of the cTOFR and the mTOFR During Reversal of Deep Neuromuscular Blockade With Sugammadex
- Cardiac Output and Recovery Time (NA)
- NMBA Reversal and Postoperative Urinary Retention
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUGAMMADEX SODIUM CI brief — competitive landscape report
- SUGAMMADEX SODIUM updates RSS · CI watch RSS